FDA Approval Activities for this Drug…

NIMOTOP (nimodipine) Capsules,30 mg, Bayer Pharmaceutical Division NDA 18-869/S10 8/22/00 8/23/00 8/23/00 NIMOTOP (nimodipine) Capsules,Rx Bayer Pharmaceutical Division NDA 18-869 8/22/00 Nimotop Indications: for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranialberry aneurysms regardless of their post-ictus neurologic condition.

For the latest approval information, please see the main page.